Clostridium difficile infection (CDI) is increasingly recognized as an emerging healthcare problem of elevated importance.
INTRODUCTION
The worldwide increasing burden of Clostridium difficile infection (CDI) has converted the quest for optimal treatment strategies into one of the hottest topics in the field of nosocomial infectious diseases. The incidence of CDI have been steadily growing in the past decades [1] , partially due to an increasing awareness of the disease, but mainly because of an important increase in the susceptible population during this period, such as the elderly or the immunocompromised [2] , the appearance of BI/NAP1/027 [3] and other hypervirulent C.
difficile strains and a growing prevalence of asymptomatic C. difficile carriage [4] . Patients with CDI have increased length of hospital stay, higher readmission rates, more elevated inpatient costs and higher mortality than patients without CDI [5] [6] [7] .
Boards of experts approving clinical guidelines constantly have to cope with the lack of sound scientific evidence on important aspects of CDI management, such as the precise definition of CDI severity [8] [9] [10] [11] , duration of contact isolation measures [12] , or the indications and optimal time of surgical intervention [13] . The consequence of this situation is the coexistence of guidelines with certain differences in their recommendations that may raise doubts in the minds of treating physicians at the time of clinical decision making [14] . This insecurity, in turn, may also contribute to the low adherence to existing guidelines observed in various studies [15] [16] [17] .
Indeed, an elevated proportion of clinicians agree on the main points where current CDI management practices could and should be improved [18] .
In the following, we present a critical summary and comparison of the latest international guidelines published by five international societies on the management of CDI, and briefly discuss some of the most controversial and currently unresolved questions in this field in the light of the most up-to-date available evidence. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
CURRENT GUIDELINES ON CDI MANAGEMENT
There are a number of guidelines and recommendations on the prevention and treatment of CDI approved by national expert boards in various countries [19] [20] [21] [22] [23] [24] [25] . In this article, however, we will center our attention on seven international guidelines published in the last 6 years, reviewing and comparing their recommendations on three fundamental aspects of CDI management: contact isolation measures, pharmacological therapy, and surgical treatment. [33] which is referred to by the previous, 2011 treatment guidelines as the one recommended to follow. The recommendations of these two guidelines supported by the ESCMID and the ASID will also be taken into consideration in the following analysis.
The ASID document on CDI management
[31] does not indicate recommendation strength and evidence quality, whereas the ASID/AICA guidelines on CDI prevention [33] use the same grading system as the IDSA/SHEA 
CONTACT ISOLATION MEASURES
Human-to-human transmission of C. difficile was first suspected in the early 1980s [34] , and today there is wide consensus on the importance of applying contact isolation measures in diagnosed CDI cases. The examined guidelines, however, differ in certain details in their recommendations in this respect which are worth mentioning.
Whereas hand washing with soap and water is only recommended in the outbreak setting or in cases of elevated CDI rate according to the IDSA/ SHEA guidelines, and the ASID/AICA recommend it only in cases of not having used gloves and directly soiled hands, the rest of the societies strongly recommend the use of soap and water after being in contact with CDI patients.
The duration of contact precautions until at least 48 h after diarrhea resolution is a point emphasized by the non-US guidelines, whereas the IDSA/SHEA and ACG guidelines do not make clear recommendations on the exact time of discontinuation of contact precautions They refer instead to ''the resolution of diarrhea'' as a necessary condition for this, without further specifications, although the 48-hour-rule is mentioned as a possible strategy by the ACG guidelines.
There is consensus among the five guidelines in the preference of chlorine-containing disinfection agents for the cleaning of patient rooms and the equipment used in CDI cases.
The minimum allowed chlorine concentration of these solutions, however, is higher in the ACG guidelines than the other documents (5000 vs. 1000 ppm). The ASID/AICA and the ESCMID guidelines also emphasize the importance of thorough terminal room cleaning after discharge or transfer of a CDI patient, and the ESCMID also recommends additional immediate cleaning to take place in cases of environmental fecal contamination. The details of the individual recommendations are summarized in Table 1 .
Unresolved Issues
According to recent evidence, stool, skin, and environmental contamination after a resolved CDI episode persist in a considerable proportion of cases, and C. difficile shedding by cured patients may be as high as 50% 1-4 weeks after the end of treatment [12] . This phenomenon can lead to a higher hand contamination rate of healthcare personnel caring for these patients that, in turn, may increase the risk of in-ward C. difficile transmission [35] . In light of these data, maintaining contact precautions after a treated CDI episode until discharge may be of potential benefit in terms of CDI spread control. Related to this problem is the screening of asymptomatic C. difficile carriers at hospital admission, which has recently also been in the focus of attention. Apart from a series of mathematical models that demonstrate the cost-effectiveness of this practice [36] [37] [38] , a recent quasi-experimental study reported a significant decrease in CDI incidence after the implementation of this measure [39] . If the screening of potential C. difficile carriers in the hospital will ever form part of guideline recommendations depends on the results of future studies addressing this issue. 
PHARMACOLOGICAL THERAPY
The summary of pharmacological treatment recommendations of the five CDI guidelines can be found in Table 2 .
Initiation of Pharmacological Treatment
All five expert boards lay special emphasis in their recommendations on the withdrawal of This last document also suggests the prompt initiation of empiric therapy in the particular case of severe colitis in a patient with inflammatory bowel disease (conditional recommendation, low-quality evidence). The ASID guidelines chose a different approach to this problem, advising laboratories to perform automatic tests for the presence of toxigenic C. difficile on every unformed stool sample they receive from hospitalized patients, even in the absence of the specific request form.
Unresolved Issues
Empirical treatment of CDI before the collection of stool specimens may be inevitable in certain cases, as recommended by three of the five analyzed guidelines. It has to be borne in mind, however, that the proportion of a false negative microbiological test may reach 14% after 1 day, and up to 45% after 3 days, of treatment, independently from the detection method used [40] . These same three guidelines accept the use of PCR on rectal swab specimens for CDI diagnosis in patients with ileus, but there are no recommendations about the use of this method in the case of an anticipated delay in stool specimen collection for other reasons.
On the other hand, PCR tests without the direct detection of C. difficile toxins may lead to overdiagnosis of CDI, as it cannot differentiate between infection and colonization [41] , and an erroneous diagnosis of CDI may lead to unnecessary treatment and to the delay in some cases of further efforts to find the real cause of the symptoms.
Treatment Choice According to CDI Severity
The appearance of life-threatening complications, such as shock, bowel perforation or peritonitis, are clear signs of a severe CDI, but there is considerably less consensus on other patient and/or disease parameters that would predict an unfavorable disease course and warrant a more aggressive initial therapy. Although all examined guidelines differentiate between mild-moderate and severe CDI, there are great differences among the exact criteria they use to define these categories.
The ESCMID guidelines recognize the difficulty of precisely defining CDI severity, [8, 44, 47] . It seems evident that the precise impact of age on CDI severity needs further clarification. The burden of comorbid conditions is also known to be associated with a severe course of CDI [8, 42] , and yet it is only mentioned in [48, 66] , and Horn's index [67] . All of them have demonstrated good correlation with CDI severity and poor outcome. The superiority of any of these comorbidity scales over the rest has not been investigated in this respect, but there seems to be sufficient evidence available for their future inclusion among CDI severity risk factors.
In contrast to age and comorbidity, computer tomography (CT) findings and the presence of pseudomembranes as evidenced by colonoscopy are both included as markers of severe disease in more than one current set of guidelines [28, 31], albeit based on rather dubious scientific evidence. Although CT scan is a useful tool to diagnose toxic megacolon [68] , other specific radiological findings do not seem to correlate indubitably well with CDI severity [69, 70] . Similarly, endoscopic findings with or without colon biopsy may help clarifying diarrhea etiology in cases of a high clinical suspicion and a negative C. difficile stool test [71] , but the presence of pseudomembranous colitis seems to be a less CDI-specific finding than it is generally believed to be [72] , and its relationship with severe outcome has not been demonstrated either [73] . Oral vancomycin combined with intravenous metronidazole is the treatment of choice in severe-complicated CDI according to the IDSA/SHEA and ACG guidelines. This combination was recently reported to be superior to vancomycin monotherapy in terms of mortality in a retrospective study in critically ill CDI patients [74] , but a posterior animal model did not confirm these results [75] , and a meta-analysis comparing the efficacy and safety of vancomycin therapy with combination regimens did not find any benefit of this combination either [76] . Moreover, this last study demonstrated a higher rate of adverse events (including higher mortality) in patients receiving combination therapy. More recent for recurrent disease, whereas the use of metronidazole is only marginally supported in this setting (recommendation C-I). Moreover, the most recent ASID document directly discourages from using metronidazole in recurrent CDI.
Unresolved Issues
General consensus on the precise definition of the patient population at an elevated recurrence risk is still lacking, though the evidence available is somewhat more consistent than in the case of disease severity. The risk factors listed by the ESCMID guidelines are largely in accordance with the conclusions of two meta-analyses and a systematic review performed on this topic [42, 77, 78] . More recent studies greatly support these previous results, but also name additional risk factors for recurrent CDI not mentioned by any of the current guidelines. In a retrospective, but very extensive cohort, steroid treatment was found to be associated with recurrent CDI [79] , and a very recent prospective cohort identified enteral tube nutrition as another independent predictor of recurrence [80] . In another report on a retrospective cohort of more than 750 patients, the authors found a longer hospital stay to independently predict recurrent CDI [81] , and there is growing evidence that inflammatory bowel disease may also predispose to CDI recurrence [82] . It is also important to mention that proton pump inhibitor treatment, although it has been associated with CDI relapse on multiple occasions [78, 81, 83] 
The role of fidaxomicin in multiple recurrent CDI is unquestionable today. There is growing evidence, however, demonstrating that it may be more cost-effective than vancomycin or metronidazole in recurrent CDI and also as a first-line treatment [90] [91] [92] [93] . In a study presenting real-world data on fidaxomicin use in seven English hospitals, the most significant reduction in CDI recurrence rates after the introduction of fidaxomicin was observed in the centers where it was used as first-line treatment in all CDI cases [94] . Fidaxomicin use, moreover, seems to lead to less environmental C. difficile contamination, which may have a positive impact on in-hospital C. difficile spread [95] , and since it does not significantly alters gut microbiota, its use may also reduce the risk of intestinal colonization by multiresistant bacteria in comparison with vancomycin treatment [96] . If these data are confirmed by forthcoming studies, fidaxomicin will probably gain a more central role in CDI treatment.
The administration of vancomycin via nasogastric tube is a generally accepted practice, but fidaxomicin is only recommended by current guidelines to be administered orally. According to recent data, this may be a safe and efficient treatment option when oral intake is impossible [97] [98] [99] . Future guidelines may consider this fidaxomicin administration method for CDI patients with an elevated recurrence risk and impaired oral intake.
Intestinal microbiota transplantation represents an approach that is markedly different from other current CDI therapies that may even have a deleterious collateral effect on the intestinal microbiota [100] . Despite the need of a rather complex infrastructure to perform this intervention [101] [102] [103] , its advantages clearly outweigh the inconveniences. Due to the reconstitution of a healthy intestinal microbiota, this treatment method has demonstrated an excellent clinical efficacy in recurrent CDI [104] , and has also been proved to be cost-effective as compared to vancomycin and even fidaxomicin [91, 105, 106] . It is becoming available in an increasing number of centers worldwide, and the recently demonstrated efficacy of frozen and encapsulated microbiota administered orally makes it an ever more attractive treatment choice [107] . Based on these promising results, it may only be a matter of time until oral microbiota therapy becomes the backbone of the treatment of recurrent and refractory CDI.
Probiotics and Immunotherapy
The role of probiotics and immunotherapy in CDI is controversial, and this is clearly reflected in the discordant recommendations on their use among the examined guidelines. antibiotic treatment [108] . Hence, they may be considered for this indication by future guidelines.
The recommendations regarding immunotherapy may also change substantially in the future, given that the monoclonal antibody bezlotoxumab efficiently prevented CDI recurrence in two recent randomized controlled trials [109] . Moreover, there are also various vaccines against C. difficile under development, the most advanced of which [110] is currently being evaluated in a phase III clinical trial (NCT01887912). Subtotal colectomy with the preservation of the rectum and end-ileostomy is the intervention of choice for the surgical treatment of CDI. Based on a case-controlled series published in 2011, however, diverting loop ileostomy and colonic lavage followed by intravenous metronidazole and vancomycin administered via the efferent limb of the ileostomy seems to be a good alternative to total colectomy in selected patients [111] . This novel colon-sparing method is mentioned by the ACG, ESCMID and ASID guidelines, and obtains a 2-C recommendation level in the WSES document.
SURGICAL TREATMENT

Unresolved Issues
An emergency surgical intervention is indicated without any doubt in cases of colonic perforation and peritonitis. However, the exact patient population that could benefit from non-emergency surgery, and the optimal time-point of such an intervention are issues less clearly defined. According to two meta-analyses, prompt surgical intervention can reduce mortality in severe CDI [13, 112] . However, the authors of both of these studies admit that the optimal time-point for surgery is difficult to identify. 
